Drug intelligence / Profile preview

cetuximab + irinotecan + vemurafenib

Development stage: Unknown
Lead developer: SWOG Cancer Research Network
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A triple drug combination therapy used for the treatment of BRAF V600E-mutant metastatic colorectal cancer. This regimen combines cetuximab (an EGFR inhibitor), irinotecan (a topoisomerase I inhibitor), and vemurafenib (a BRAF V600E inhibitor) to simultaneously target multiple cancer growth pathways. Clinical trials have shown this combination significantly improves progression-free survival and response rates compared to cetuximab and irinotecan alone.

Other names: VICtriple therapytriple combination

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)BRAF V600ETOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on cetuximab + irinotecan + vemurafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetuximab + irinotecan + vemurafenib.

Explore the full profile